Argus upgrades Catalent to buy, cites transition to biologics production (CTLT)

0


Test tube with DNA

Andy

Argus had upgraded Catalent (NYSE:CTLT) to buy, citing the company’s transition from COVID products to commercializing biologics and gene therapies.

The research group noted that Catalent is partnered with Novo Nordisk (NVO) for the production of Wegovy, with other GLP-1



Source link

Leave A Reply

Your email address will not be published.